Literature DB >> 22438246

Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection.

Shokrollah Elahi1, Toshiro Niki, Mitsuomi Hirashima, Helen Horton.   

Abstract

Galectin-9 (Gal-9) is a tandem repeat-type member of the galectin family and is a ligand for T-cell immunoglobulin mucin domain 3 (Tim-3), a type-I glycoprotein that is persistently expressed on dysfunctional T cells during chronic infection. Studies in autoimmune diseases and chronic viral infections show that Tim-3 is a regulatory molecule that inhibits Th1 type immune responses. Here we show that soluble Gal-9 interacts with Tim-3 expressed on the surface of activated CD4(+) T cells and renders them less susceptible to HIV-1 infection and replication. The Gal-9/Tim-3 interaction on activated CD4(+) T cells, leads to down-regulation of HIV-1 coreceptors and up-regulation of the cyclin-dependent kinase inhibitor p21 (also known as cip-1 and waf-1). We suggest that higher expression of Tim-3 during chronic infection has evolved to limit persistent immune activation and associated tissue damage. These data demonstrate a novel mechanism for Gal-9/Tim-3 interactions to induce resistance of activated CD4(+) T cells to HIV-1 infection and suggest that Gal-9 may play a role in HIV-1 pathogenesis and could be used as a novel microbicide to prevent HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22438246      PMCID: PMC3359739          DOI: 10.1182/blood-2011-11-389585

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  HIV vaccine research: the way forward.

Authors:  Anthony S Fauci; Margaret I Johnston; Carl W Dieffenbach; Dennis R Burton; Scott M Hammer; James A Hoxie; Malcolm Martin; Julie Overbaugh; David I Watkins; Adel Mahmoud; Warner C Greene
Journal:  Science       Date:  2008-07-25       Impact factor: 47.728

2.  Primitive hematopoietic cells resist HIV-1 infection via p21.

Authors:  Jielin Zhang; David T Scadden; Clyde S Crumpacker
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

3.  Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes.

Authors:  Ying Zhang; Cheng J Ma; Jia M Wang; Xiao J Ji; Xiao Y Wu; Jonathan P Moorman; Zhi Q Yao
Journal:  J Leukoc Biol       Date:  2011-08-15       Impact factor: 4.962

4.  Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis.

Authors:  Masako Seki; Souichi Oomizu; Ken-Mei Sakata; Atsuko Sakata; Tomohiro Arikawa; Kota Watanabe; Kanako Ito; Keisuke Takeshita; Toshiro Niki; Naoki Saita; Nozomu Nishi; Akira Yamauchi; Shigeki Katoh; Akihiro Matsukawa; Vijay Kuchroo; Mitsuomi Hirashima
Journal:  Clin Immunol       Date:  2008-02-20       Impact factor: 3.969

5.  Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices.

Authors:  Atsuya Nobumoto; Keiko Nagahara; Souichi Oomizu; Shigeki Katoh; Nozomu Nishi; Keisuke Takeshita; Toshiro Niki; Akira Tominaga; Akira Yamauchi; Mitsuomi Hirashima
Journal:  Glycobiology       Date:  2008-06-25       Impact factor: 4.313

6.  Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy.

Authors:  Haorile Chagan-Yasutan; Hiroki Saitoh; Yugo Ashino; Tomohiro Arikawa; Mitsuomi Hirashima; Shenwei Li; Motoki Usuzawa; Shigeru Oguma; Elizabeth Freda O Telan; Chikwelu Larry Obi; Toshio Hattori
Journal:  Tohoku J Exp Med       Date:  2009-08       Impact factor: 1.848

7.  The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages.

Authors:  Anna Bergamaschi; Annie David; Erwann Le Rouzic; Sébastien Nisole; Françoise Barré-Sinoussi; Gianfranco Pancino
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

8.  Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.

Authors:  Keiko Nagahara; Tomohiro Arikawa; Souichi Oomizu; Keiichi Kontani; Atsuya Nobumoto; Hiroaki Tateno; Kota Watanabe; Toshiro Niki; Shigeki Katoh; Minoru Miyake; Syun-Ichiro Nagahata; Jun Hirabayashi; Vijay K Kuchroo; Akira Yamauchi; Mitsuomi Hirashima
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

9.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

10.  Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.

Authors:  R Brad Jones; Lishomwa C Ndhlovu; Jason D Barbour; Prameet M Sheth; Aashish R Jha; Brian R Long; Jessica C Wong; Malathy Satkunarajah; Marc Schweneker; Joan M Chapman; Gabor Gyenes; Bahareh Vali; Martin D Hyrcza; Feng Yun Yue; Colin Kovacs; Aref Sassi; Mona Loutfy; Roberta Halpenny; Desmond Persad; Gerald Spotts; Frederick M Hecht; Tae-Wook Chun; Joseph M McCune; Rupert Kaul; James M Rini; Douglas F Nixon; Mario A Ostrowski
Journal:  J Exp Med       Date:  2008-11-10       Impact factor: 14.307

View more
  55 in total

1.  Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL.

Authors:  Elizabeth Connick; Joy M Folkvord; Katherine T Lind; Eva G Rakasz; Brodie Miles; Nancy A Wilson; Mario L Santiago; Kimberly Schmitt; Edward B Stephens; Hyeon O Kim; Reece Wagstaff; Shengbin Li; Hadia M Abdelaal; Nathan Kemp; David I Watkins; Samantha MaWhinney; Pamela J Skinner
Journal:  J Immunol       Date:  2014-10-31       Impact factor: 5.422

Review 2.  Unravelling the mechanisms of durable control of HIV-1.

Authors:  Bruce D Walker; Xu G Yu
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

Review 3.  Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis.

Authors:  Florent Colomb; Leila B Giron; Irena Trbojevic-Akmacic; Gordan Lauc; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

Review 4.  CROI 2016: Basic Science Review.

Authors:  Mario Stevenson
Journal:  Top Antivir Med       Date:  2016 May-Jun

Review 5.  Galectin-9: From cell biology to complex disease dynamics.

Authors:  Sebastian John; Rashmi Mishra
Journal:  J Biosci       Date:  2016-09       Impact factor: 1.826

Review 6.  Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Authors:  Lisa J Henderson; Lauren B Reoma; Joseph A Kovacs; Avindra Nath
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

7.  Galectin-9 binds to O-glycans on protein disulfide isomerase.

Authors:  Katrin Schaefer; Nicholas E Webb; Mabel Pang; Jenny E Hernandez-Davies; Katharine P Lee; Pascual Gonzalez; Martin V Douglass; Benhur Lee; Linda G Baum
Journal:  Glycobiology       Date:  2017-09-01       Impact factor: 4.313

8.  A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(+) T cells from elite controllers.

Authors:  Jin Leng; Hsin-Pin Ho; Maria J Buzon; Florencia Pereyra; Bruce D Walker; Xu G Yu; Emmanuel J Chang; Mathias Lichterfeld
Journal:  Cell Host Microbe       Date:  2014-06-11       Impact factor: 21.023

9.  T-cell immunoglobulin- and mucin-domain-containing molecule 3 genetic variants and HIV+ non-Hodgkin lymphomas.

Authors:  Haihan Song; Shaolin Ma; Zhanshan Cha; Lei Chen; Danian Tong; Lan Ma; Weiguo Song; Jianwen Bai
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

10.  Restriction of Human Cytomegalovirus Infection by Galectin-9.

Authors:  Allison Abendroth; Brian P McSharry; Barry Slobedman; Emily A Machala; Selmir Avdic; Lauren Stern; Dirk M Zajonc; Chris A Benedict; Emily Blyth; David J Gottlieb
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.